New drug combo for hard-to-treat B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (lisaftoclax, chidamide, and rituximab) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatments. The goal is to see if this combination can help patients whose disease hasn't responded to standard chemotherapy and who aren't candidates for stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) with a specific marker (BCL-2) present in at least 30% of cancer cells
- Cancer has returned or stopped responding after at least one prior treatment that included chemotherapy and an anti-CD20 antibody (like rituximab)
- Not eligible for or willing to pursue autologous stem cell transplantation
- Good overall health and functional status (able to care for self with minimal or no assistance)
- Adequate organ function (healthy bone marrow, liver, and kidney function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
This trial tests a new drug called Lisatoclax added to standard chemotherapy (R-CHOP or Pola-R-CHP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better and is safe.
This trial tests a new combination of drugs (chidamide, lisaftoclax, and standard chemotherapy) to treat a serious type of blood cancer called double-hit or triple-hit diffuse large B-cell lymphoma. The goal is to see if adding these newer drugs to standard treatment improves how well the cancer responds.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new combination of three drugs (golcadomide, poseltinib, and rituximab) for people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. It may be an option if you cannot have a stem cell transplant.
Hear when a new Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.